Purpose—We investigated the in vitro and in vivo anti-MM activity of mAb 1339, a high-affinity fully humanized anti-IL-6 mAb (IgG1), alone and in combination with conventional and novel anti- MM agents, as well as its effect on bone turnover. Experimental Design—We examined the growth inhibitory effect of 1339 against MM cell lines in the absence and in the presence of bone marrow stromal cells (BMSC) alone or in combination with dexamethasone, bortezomib, perifosine and revlimid. Using the SCID-hu murine model of MM, we also examined the effect of 1339 on MM cell growth and MM bone disease. Results—mAb 1339 significantly inhibited growth of MM cell in the presence of BMSC in vitro, associated with inhibition of phosphorylation of STAT3, ERK1/2 and Akt. In addition, mAb 1339 enhanced cytotoxicity induced by dexamethasone as well as bortezomib, lenalidomide, and perifosine in a synergistic fashion. Importantly mAb 1339 significantly enhanced growth inhibitory effects of dexamethasone in vivo in SCID-hu mouse model of MM. mAb 1339 treatment also resulted in inhibition of osteoclastogenesis in vitro and bone remodeling in SCID-hu model.

A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma / M. T., Fulciniti; T., Hideshima; C., Vermot Desroches; Pozzi, Samantha; P., Nanjappa; Z., Shen; N., Patel; E. S., Smith; R., Prabhala; Y., Tai; P., Tassone; K. C., Anderson; N. C., Munshi. - In: CLINICAL CANCER RESEARCH. - ISSN 1557-3265. - ELETTRONICO. - 15:23(2009), pp. 7144-7152. [10.1158/1078-0432.CCR-09-1483]

A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma

POZZI, Samantha;
2009

Abstract

Purpose—We investigated the in vitro and in vivo anti-MM activity of mAb 1339, a high-affinity fully humanized anti-IL-6 mAb (IgG1), alone and in combination with conventional and novel anti- MM agents, as well as its effect on bone turnover. Experimental Design—We examined the growth inhibitory effect of 1339 against MM cell lines in the absence and in the presence of bone marrow stromal cells (BMSC) alone or in combination with dexamethasone, bortezomib, perifosine and revlimid. Using the SCID-hu murine model of MM, we also examined the effect of 1339 on MM cell growth and MM bone disease. Results—mAb 1339 significantly inhibited growth of MM cell in the presence of BMSC in vitro, associated with inhibition of phosphorylation of STAT3, ERK1/2 and Akt. In addition, mAb 1339 enhanced cytotoxicity induced by dexamethasone as well as bortezomib, lenalidomide, and perifosine in a synergistic fashion. Importantly mAb 1339 significantly enhanced growth inhibitory effects of dexamethasone in vivo in SCID-hu mouse model of MM. mAb 1339 treatment also resulted in inhibition of osteoclastogenesis in vitro and bone remodeling in SCID-hu model.
2009
15
23
7144
7152
A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma / M. T., Fulciniti; T., Hideshima; C., Vermot Desroches; Pozzi, Samantha; P., Nanjappa; Z., Shen; N., Patel; E. S., Smith; R., Prabhala; Y., Tai; P., Tassone; K. C., Anderson; N. C., Munshi. - In: CLINICAL CANCER RESEARCH. - ISSN 1557-3265. - ELETTRONICO. - 15:23(2009), pp. 7144-7152. [10.1158/1078-0432.CCR-09-1483]
M. T., Fulciniti; T., Hideshima; C., Vermot Desroches; Pozzi, Samantha; P., Nanjappa; Z., Shen; N., Patel; E. S., Smith; R., Prabhala; Y., Tai; P., Ta...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/860195
Citazioni
  • ???jsp.display-item.citation.pmc??? 46
  • Scopus 105
  • ???jsp.display-item.citation.isi??? 95
social impact